Toward a Cure ... What's New?
12/27/2011 | FRAXA Research Outlook 2012 - Treatment Trials and the Next Wave of New Drugs
Fragile X research continues to progress at a break-neck pace and 2012 promises to be a watershed year: the landscape may be very different by this time next year!
12/27/2011 | 2011 Preliminary Financial Report
Thank you to everyone who helped FRAXA meet our 2011 Annual Appeal Goal!
10/31/2011 | Knockout Rat Model for Fragile X: coming in 2012
Genetically engineered Fragile X Knockout mice will give scientists a powerful new key to understanding the learning problems seen in Fragile X.
12/4/2011 | Learn More about Clinical trials of new treatments for Fragile X and how to participate
Experimental new drugs, AFQ056 (an mGluR5 antagonist from Novartis) and STX209 (arbaclofen from Seaside Therapeutics) are in large scale trials. New sites are accepting participants.
12/5/2011 | Our 2011 Annual Appeal Goal
Please help FRAXA raise $400,000 to enable our research teams to work toward a cure!